Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations

Inclusion Criteria:

1. Fully informed about the study and voluntarily sign the informed consent form (ICF).

2. Age ≥ 18 years.

3. Safety Lead-In Phase: Patients with gliomas of a documented IDH1 and/or IDH2mutation. Perioperative Study Phase: Patients with gliomas of definitive orsuspected IDH1 and/or IDH2 mutations scheduled for surgery.

4. All patients must have at least one measurable lesion.

5. Karnofsky Performance Status (KPS) score ≥ 80% .

6. In the investigator's judgment, a life expectancy of ≥ 12 weeks.

7. Sufficient bone marrow and organ function.

Exclusion Criteria:

1. Previous treatment with IDH inhibitors.

2. Unresolved toxicity from previous antitumor treatments not reverted to ≤ Grade 1 (except for alopecia, skin pigmentation changes, and ≤ Grade 2 peripheralneuropathy).

3. Patients assessed by researchers to have high-risk or unstable conditions.

4. Having other malignancies or a history of other malignancies within 5 years prior toscreening.

5. History of clinically significant liver disease, including active infection withviral hepatitis, or other active hepatitis, alcoholic liver disease, cirrhosis, etc.

6. Patients with HIV infection.

7. Pregnancy (positive pregnancy test before dosing) or currently breastfeeding women.

8. Presence of diseases or conditions affecting drug absorption.

9. Any other conditions, in the investigator's judgment, unsuitable for the study drug,will result in exclusion.